www.melanexjou.fora.pl

[phqi2hyougj]

Shares of WuXi PharmaTech Cayman Inc. rose Thursday after a Goldman Sachs analyst started coverage of the stock with a "Buy" rating, and placed WuXi on a list of recommended stocks.
Profits should keep growing over the next two years for the Shanghai-based research and development outsourcing company,[link widoczny dla zalogowanych], said analyst Wei Du. Du said WuXi is in a better competitive position than its rivals,[link widoczny dla zalogowanych], and China may become a top research outsourcing market for drugmakers in developing countries.
He put the stock on the "Conviction Buy List," and WuXi shares gained $1.25,[link widoczny dla zalogowanych], or 10.3 percent, to $13.40 in afternoon trading.
Du said laboratory service revenue should keep growing,[link widoczny dla zalogowanych], while the toxicology service and manufacturing service businesses have good potential over the coming years.
"We see strong potential for growth in WuXi's manufacturing business in the long term,[link widoczny dla zalogowanych], given its reputation and service quality," he wrote.